Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNRNP200 | O75643 | 3/20 | 0.63 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16856894 | 0.90 | SNRNP200 (0.65) | SNRNP200 | |
| SCHEMBL16856982 | 0.89 | SNRNP200 (0.67) | SNRNP200 | |
| SCHEMBL16856791 | 0.88 | SNRNP200 (0.66) | SNRNP200CDK5CDK5R1 | |
| SCHEMBL16857296 | 0.88 | SNRNP200 (0.63) | SNRNP200 | |
| SCHEMBL16857091 | 0.88 | SNRNP200 (0.63) | SNRNP200C5AR1 | |
| SCHEMBL16857085 | 0.88 | SNRNP200 (0.67) | SNRNP200C5AR1 | |
| SCHEMBL16857223 | 0.88 | SNRNP200 (0.67) | SNRNP200C5AR1 | |
| SCHEMBL16856795 | 0.88 | SNRNP200 (0.67) | SNRNP200C5AR1 | |
| SCHEMBL16857046 | 0.87 | SNRNP200 (0.62) | SNRNP200 | |
| SCHEMBL16857022 | 0.86 | SNRNP200 (0.65) | SNRNP200 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2889291-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-07-01 | — | — | EP | disclosed |
| EP-2889291-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | PTGIS, LIPG, FEN1 | SNRNP200 3216/4885C5AR1 684/4885FFAR1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.